Drugs / Alpha-methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside
Alpha-methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05558904 | Jan 2023 → Oct 2026 expected | lung adenocarcinoma | Jonsson Comprehensive Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Alpha-methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05558904 ↗ |
| Route | Intravenous | “Patients receive Me-4FDG tracer intravenously (IV)” NCT05558904 ↗ |